Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study.
Van Calster B, Van Hoorde K, Valentin L, Testa AC, Fischerova D, Van Holsbeke C, Savelli L, Franchi D, Epstein E, Kaijser J, Van Belle V, Czekierdowski A, Guerriero S, Fruscio R, Lanzani C, Scala F, Bourne T, Timmerman D; International Ovarian Tumour Analysis Group.
BMJ. 2014 Oct 15;349:g5920. doi: 10.1136/bmj.g5920.
PMID:25320247
Needleoscopic Conservative Staging of Borderline Ovarian Tumor.
Gueli Alletti S, Rossitto C, Perrone E, Cianci S, De Blasis I, Fagotti A, Scambia G.
Identification of spatially-resolved markers of malignant transformation in Intraductal Papillary Mucinous Neoplasms.
Agostini A, Piro G, Inzani F, Quero G, Esposito A, Caggiano A, Priori L, Larghi A, Alfieri S, Casolino R, Scaglione G, Tondolo V, Cammarota G, Ianiro G, Corbo V, Biankin AV, Tortora G, Carbone C.
Nat Commun. 2024 Mar 29;15(1):2764. doi: 10.1038/s41467-024-46994-2.
PMID:38553466
Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer.
Wang K, Pearlstein KA, Patchett ND, Deal AM, Mavroidis P, Jensen BC, Lipner MB, Zagar TM, Wang Y, Lee CB, Eblan MJ, Rosenman JG, Socinski MA, Stinchcombe TE, Marks LB.
Radiother Oncol. 2017 Nov;125(2):293-300. doi: 10.1016/j.radonc.2017.10.001. Epub 2017 Oct 16.
PMID:29050957
Cardiotoxic heart failure in breast cancer survivors: a concept analysis.